Combinib 250 mg

Combinib 250 mg Tablets

Generic Name: Lapatinib
Brand Name: Combinib 250 mg
Strength: 250 mg
Manufacturer: Cipla Ltd.
Form: Tablet
Dosage Form: Oral
Packaging Type: Bottle / Blister / Strip
Packaging Size: 30 Tablets per Bottle
Prescription Required: Yes
Country of Origin: Made in India
Minimum Order Quantity: 1 Bottle
Storage Conditions: Store at room temperature
Weight per Bottle: Approx. 250 gm
Expiry: Long Shelf Life

Composition:

• Active Ingredient: Lapatinib Ditosylate Equivalent to Lapatinib 250 mg

Therapeutic Indication:

Combinib is indicated for the treatment of:

• Metastatic Breast Cancer (HER2-positive), often in combination with other therapies such as capecitabine or letrozole.

Mechanism of Action:

Lapatinib is a dual tyrosine kinase inhibitor that blocks two specific enzymes (EGFR and HER2/neu receptors) responsible for the growth and survival of cancer cells. It is especially effective in HER2-positive breast cancer cases.

International Brand Equivalent:

• Tykerb® 250 mg by Novartis

Dosage & Administration:

• To be taken exactly as directed by an oncologist

• Typically taken on an empty stomach, at least 1 hour before or after meals

• Must be used in conjunction with other prescribed cancer treatments

Key Features:

• Manufactured by Cipla, a globally trusted pharmaceutical company

• Cost-effective alternative to international brands

• Supplied in a convenient 30-tablet bottle

• Suitable for clinical use and global oncology distribution

• Ideal for drop shipping and export markets due to stable shelf life and durable packaging